At first, considering the spectrum of MASLD, including fatty liver, steatohepatitis, fibrosis, cirrhosis, or liver cancer, we speculate that APOH downregulation-induced fatty liver might be an early pathologic change and could evolve into hepatitis or fibrosis during disease progression. The gene discussed is APOH; the disease is Hepatic steatosis.